MedPath

Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)

Phase 1
Completed
Conditions
Myocardial Infarction
Interventions
Procedure: Pericardial adipose pedicle (adiFLAP) transposition.
Other: Control
Registration Number
NCT01473433
Lead Sponsor
Germans Trias i Pujol Hospital
Brief Summary

The purpose of this trial is to evaluate safety and efficacy of a pericardial adipose pedicle transposition (adiFLAP) for the improvement of cardiac function in patients with a chronic myocardial infarct. Preclinical studies in the porcine model of myocardial infarction have shown that AdiFLAP reduces infarct area.

Detailed Description

This novel intervention consists of the pericardial isolation of adipose tissue maintaining its vascularization to create an adipose flap (adiFLAP) and its transposition fully covering infarcted myocardium.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Established transmural myocardial infarction non candidate to revascularization (>3 months-old)
  • Candidate to coronary by-pass for other territories different from the previous transmural infarct.
  • > 18 years of age, male or female, capable of giving an informed consent.
Exclusion Criteria
  • Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.
  • Severe valvular disease candidate for surgical restoration.
  • Candidate to ventricular remodeling.
  • Contraindication for NMR (creatinin clearance <30 ml/min/1.73m2, metallic implants, claustrophobia).
  • Severe renal or hepatic failure.
  • Abnormal laboratory tests (no explanation at the time of inclusion).
  • Previous cardiac intervention.
  • High surgical risk (Euroscore 2).
  • Pregnant or breast feeding women.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
adiFLAPPericardial adipose pedicle (adiFLAP) transposition.Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
ControlControlPatients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
Primary Outcome Measures
NameTimeMethod
Appearance of adverse effects derived from the procedure (7 days after the surgical procedure and 1 year follow-up).12 months
Secondary Outcome Measures
NameTimeMethod
Improvement of cardiac function as changes in clinical variables, cardiac magnetic resonance imaging and echocardiography, and biochemical variables (NTproBNP and high sensitivity troponin T).12 months

Trial Locations

Locations (1)

Germans Trias Research Institute; Germans Trias University Hospital

🇪🇸

Badalona, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath